PMTI Palomar Medical Technologies, Inc. (MM)

Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced today that it will preview two new products -- the Artisan™ Aesthetic System and the MaxG™ pulsed light handpiece -- at the 68th Annual Meeting of the American Academy of Dermatology (AAD) in Miami, Florida, from March 5th through March 9th.

The new Artisan Aesthetic System offers key skin resurfacing and skin rejuvenation technologies -- a fractional non-ablative laser for treating acne and surgical scars, melasma, and striae; a fractional ablative laser for resurfacing and wrinkle treatment; and a pulsed light device for treatment of pigmented and vascular lesions -- in one comprehensive system perfect for skin rejuvenation and anti-aging practices. Artisan empowers aesthetic practitioners with the ability to treat each discrete sign of aging and other undesirable skin conditions using the most appropriate technology. With Artisan, practitioners can tailor unique treatment regimens to each client's specific needs, offering the best aesthetic outcome with the least amount of downtime or disruption. The Artisan Aesthetic System is pending US FDA clearance, and Palomar will begin shipments upon clearance.

The MaxG pulsed light handpiece is a key component of the Artisan suite of technologies and is also available on the StarLux 500 laser and pulsed light platform. With more energy per pulse, greater peak power, and higher fluences than competing broadband pulsed light devices, the MaxG delivers optimally-filtered bands of light to easily and quickly clear unwanted pigment and vascularity in a comfortable, no-downtime procedure.

Joseph P. Caruso, Chief Executive Officer, commented, "We are well positioned to lead in aesthetic technology for the coming decade. We have successfully leveraged our continuous investments in research and development into two new products designed specifically for the rejuvenation practices of dermatologists and other clinicians. MaxG and Artisan are revolutionary advances in light-based aesthetic medicine that will delight practitioners and clients alike."

Attendees at the AAD Annual Meeting in Miami can learn about the MaxG handpiece and the Artisan Aesthetic System at Palomar's exhibition hall booth, #1615.

These new products are also featured on the newly-relaunched palomarmedical.com. This new website completely redefines Palomar's online experience with a feature-rich site for aesthetic practitioners, investors, and others, offering global web architecture, treatment and product feature areas, an events calendar with online registration, a full resource library, and a personalized portal for customers called MyPalomar that enables them to access key clinical and practice support content. "Our new website demonstrates our commitment to building on our successful past while establishing a superior stake for the future," said Mr. Caruso.

Mr. Caruso continued, "Palomar has always been known for its technological leadership. We are pleased that our new website highlights another competency for Palomar and our customers -- practice building. Along with our new corporate website, we promote three direct to consumer sites: lifesculpt.com, stretchmarks1.com, and scars1.com. These consumer-focused sites educate potential clients about our therapies and lead them to our customers. Through new products and new customer support, we are absolutely committed to doing more to create additional value for our customers in this tough economy."

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets.

For more information on Palomar and its products, visit Palomar's website at palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2008 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT: Palomar Medical Technologies, Inc.

Kerry McAnistan, Investor Relations Assistant

781-993-2411

ir@palomarmedical.com